Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Yunliang Cao"'
Autor:
Yanyi Lu, Hua Yang, Yunliang Cao, Yunan Wang, Mengjia Wu, Bo He, Junzhu Xu, Zixuan Su, Wen Luo, Yuyang Liu, Wei Hu
Publikováno v:
PLoS ONE, Vol 18, Iss 3, p e0282888 (2023)
Lung squamous cell carcinoma (LUSC) is the primary pathological type of lung cancer with a less favorable prognosis. This study attempts to construct a ferroptosis-associated signature associated with overall survival (OS) that can predict the progno
Externí odkaz:
https://doaj.org/article/f1824675e9f548358a1bcf9676bfee0d
Autor:
Jinshan Xu, Yunliang Cao
Publikováno v:
2022 International Conference on Knowledge Engineering and Communication Systems (ICKES).
Autor:
Yi Li, Guojun Yue, Hui Dong, Yunliang Cao, Fang Chen, Qiaoyuan Wu, Qing Luo, Yudi Dong, Ni Jiang
Publikováno v:
Anti-Cancer Drugs
Since the treatment of lung squamous cell carcinoma (SCC) was limited due to a lack of appropriate biomarkers and novel target agents. Immune checkpoint inhibitors can offer an effective treatment for patients with advanced non-small cell lung cancer
Publikováno v:
Interactive CardioVascular and Thoracic Surgery. 35
OBJECTIVES The aim of this study was to investigate the effect of preoperative radiotherapy (PrORT) on the overall survival (OS) of patients with stage ipsilateral mediastinal lymph node metastasis (N2) non-small-cell lung cancer. METHODS A total of
Lung squamous cell carcinoma (LUSC) is the primary pathological type of lung cancer with a less favourable prognosis. This study attempts to construct a ferroptosis-associated signature associated with OS, which can predict the prognosis of LUSC and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ff5cd1056ae0d29f066707efceebeeae
https://doi.org/10.21203/rs.3.rs-1597903/v1
https://doi.org/10.21203/rs.3.rs-1597903/v1